奥希替尼治疗药物监测在非小细胞肺癌合并短肠综合征中的应用:一例病例报告
本文报告一例EGFR突变非小细胞肺癌患者,接受奥希替尼80 mg/日治疗并获得部分缓解,后因肠梗阻行双筒空肠造口术导致短肠综合征。通过质谱法监测奥希替尼血浆浓度,确认吸收不良(108 ng/mL,低于预期血浆浓度第5百分位数),并据此将剂量调整为120 mg/日,使血药浓度达到161 ng/mL,以维持肿瘤控制。
要点
- 短肠综合征可导致口服靶向药物吸收不良,TDM有助于识别。
- 奥希替尼108 ng/mL低于预期第5百分位数,提示吸收不良。
- 剂量增至120 mg/日后血药浓度161 ng/mL,可维持肿瘤控制。
核心结论
- 短肠综合征患者口服奥希替尼可能吸收不良,治疗药物监测可指导剂量调整以维持有效血药浓度。
研究设计与样本
- 病例报告:一例EGFR突变非小细胞肺癌患者,奥希替尼80 mg/日治疗后因肠梗阻行双筒空肠造口术致短肠综合征,采用质谱法监测血浆奥希替尼浓度。
主要发现
- 患者奥希替尼血浆浓度为108 ng/mL,低于预期血浆浓度第5百分位数,确认吸收不良。
关键数值与推荐
- 奥希替尼108 ng/mL低于预期血浆浓度第5百分位数;剂量增至120 mg/日后血药浓度达161 ng/mL。
临床怎么用
- 对合并短肠综合征等吸收不良风险的患者,可考虑监测奥希替尼血浆浓度并个体化调整剂量。
局限性
- 单例病例报告,结果无法推广至所有短肠综合征患者;未报告长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
引用
- Longuespée R, Kunz J, Fresnais M, et al. Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report. Br J Clin Pharmacol. 2023. PMID: 37815301. doi:10.1111/bcp.15924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。